Mer­ck’s Keytru­da nears $21B in sales, dou­bles down on com­bo tri­als

Mer­ck’s can­cer im­munother­a­py Keytru­da notched sales of $20.9 bil­lion in 2022, ce­ment­ing its sta­tus as one of the world’s top-sell­ing drugs. How­ev­er, it’s far from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER